Treasurer of the State of North Carolina’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $37.5M | Sell |
60,132
-250
| -0.4% | -$170K | 0.1% | 176 |
|
|
2026
Q1 | $46.7M | Buy |
60,382
+2,574
| +4% | +$1.97M | 0.15% | 119 |
|
|
2025
Q4 | $44.6M | Sell |
57,808
-6,053
| -9% | -$4.11M | 0.14% | 122 |
|
|
2025
Q3 | $35.9M | Sell |
63,861
-4,865
| -7% | -$2.75M | 0.11% | 159 |
|
|
2025
Q2 | $36.1M | Buy |
68,726
+19,968
| +41% | +$11.1M | 0.12% | 169 |
|
|
2025
Q1 | $30.9M | Sell |
48,758
-9,365
| -16% | -$6.44M | 0.12% | 157 |
|
|
2024
Q4 | $41.4M | Sell |
58,123
-490
| -0.8% | -$411K | 0.16% | 104 |
|
|
2024
Q3 | $61.6M | Sell |
58,613
-494
| -0.8% | -$550K | 0.25% | 69 |
|
|
2024
Q2 | $62.1M | Buy |
59,107
+1,541
| +3% | +$1.49M | 0.26% | 64 |
|
|
2024
Q1 | $55.4M | Sell |
57,566
-1,042
| -2% | -$991K | 0.24% | 79 |
|
|
2023
Q4 | $51.5M | Buy |
58,608
+230
| +0.4% | +$189K | 0.25% | 79 |
|
|
2023
Q3 | $48M | Sell |
58,378
-590
| -1% | -$464K | 0.26% | 72 |
|
|
2023
Q2 | $42.4M | Sell |
58,968
-399
| -0.7% | -$308K | 0.22% | 87 |
|
|
2023
Q1 | $48.8M | Buy |
59,367
+387
| +0.7% | +$292K | 0.28% | 73 |
|
|
2022
Q4 | $42.6M | Buy |
58,980
+3,850
| +7% | +$2.84M | 0.26% | 82 |
|
|
2022
Q3 | $38M | Buy |
55,130
+959
| +2% | +$604K | 0.25% | 78 |
|
|
2022
Q2 | $32M | Buy |
54,171
+2,249
| +4% | +$1.46M | 0.2% | 99 |
|
|
2022
Q1 | $36.3M | Buy |
51,922
+1,900
| +4% | +$1.2M | 0.2% | 99 |
|
|
2021
Q4 | $31.6M | Buy |
50,022
+876
| +2% | +$539K | 0.17% | 118 |
|
|
2021
Q3 | $29.7M | Buy |
49,146
+927
| +2% | +$575K | 0.17% | 119 |
|
|
2021
Q2 | $26.9M | Buy |
48,219
+2,136
| +5% | +$1.08M | 0.16% | 137 |
|
|
2021
Q1 | $21.8M | Buy |
46,083
+806
| +2% | +$392K | 0.14% | 147 |
|
|
2020
Q4 | $21.9M | Buy |
45,277
+540
| +1% | +$291K | 0.15% | 141 |
|
|
2020
Q3 | $25M | Buy |
44,737
+1,255
| +3% | +$761K | 0.19% | 109 |
|
|
2020
Q2 | $27.1M | Buy |
43,482
+2,857
| +7% | +$1.62M | 0.22% | 90 |
|
|
2020
Q1 | $19.8M | Buy |
40,625
+2,843
| +8% | +$1.17M | 0.18% | 121 |
|
|
2019
Q4 | $14.2M | Buy |
37,782
+360
| +1% | +$121K | 0.12% | 180 |
|
|
2019
Q3 | $10.4M | Sell |
37,422
-14,987
| -29% | -$4.43M | 0.09% | 201 |
|
|
2019
Q2 | $16.4M | Buy |
52,409
+720
| +1% | +$240K | 0.1% | 192 |
|
|
2019
Q1 | $21.2M | Buy |
51,689
+1,310
| +3% | +$539K | 0.14% | 162 |
|
|
2018
Q4 | $18.8M | Buy |
50,379
+548
| +1% | +$201K | 0.14% | 160 |
|
|
2018
Q3 | $20.1M | Buy |
49,831
+17,045
| +52% | +$6.49M | 0.13% | 172 |
|
|
2018
Q2 | $11.3M | Buy |
32,786
+20,521
| +167% | +$6.42M | 0.12% | 179 |
|
|
2018
Q1 | $4.22M | Buy |
+12,265
| New | +$4.27M | 0.11% | 201 |
|
Other funds holding REGN
Treasurer of the State of North Carolina's REGN Position: Q2 2026 in Review
Treasurer of the State of North Carolina reduced its Regeneron Pharmaceuticals (REGN) stake by 0.41% in Q2 2026, selling an estimated $170K and leaving 60,132 shares worth $37.5M. The position accounts for 0.1% of the portfolio, ranked #176.
Treasurer of the State of North Carolina first reported a position in REGN in Q1 2018 and has held it in 34 quarters since. The position peaked at $62.1M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Treasurer of the State of North Carolina held 60,132 shares of Regeneron Pharmaceuticals worth $37.5M as of Q2 2026.
- Treasurer of the State of North Carolina sold 250 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $170K.
- Regeneron Pharmaceuticals made up 0.1% of Treasurer of the State of North Carolina's portfolio in Q2 2026, its #176 holding.
- Treasurer of the State of North Carolina first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 34 quarters since.
- Treasurer of the State of North Carolina's Regeneron Pharmaceuticals position peaked at $62.1M in Q2 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Treasurer of the State of North Carolina's 13F filing for Q2 2026, filed 14 Aug 2026.